Objective: Lung inflammation causes perivascular fluid cuffs to form around extra-alveolar blood vessels; however, the physiologic consequences of such cuffs remain poorly understood. Herein, we tested the hypothesis that perivascular fluid cuffs, without concomitant alveolar edema, are sufficient to decrease lung compliance.
T he pulmonary endothelium normally serves as a tightly regulated barrier between blood and interstitium. However, endothelial barrier function is compromised in the blood vessels of critically ill patients with acute lung injury or acute respiratory distress syndrome (ARDS). Endothelial cell barrier disruption causes fluid accumulation in the lung parenchyma, which ultimately leads to inefficient gas exchange and decreased alveolar ventilation, and also in perivas-cular spaces surrounding extra-alveolar arteries and veins (1) . Traditional thinking advocates that capillary endothelial cell barrier disruption increases interstitial fluid accumulation that is pulled by negative interstitial pressure into perivascular spaces of larger vessels as a safety mechanism that limits alveolar flooding. However, recent acute lung injury and pulmonary edema animal models indicate that extra-alveolar vessels exhibit greater permeability responses than do capillaries, both at baseline (2) (3) (4) and in response to a variety of inflammatory stimuli (5) (6) (7) (8) (9) . Furthermore, these experimental findings illustrate that fluid can directly traverse across extra-alveolar vessels and accumulate in perivascular cuffs (7) . Whereas some inflammatory agonists exert their actions on extra-alveolar endothelium, others disrupt the capillary endothelial cell barrier and cause alveolar flooding in the absence of perivascular cuffs (6, 10) . Thus, it appears that perivascular cuff formation and alveolar flooding represent distinct physiologic processes that are regulated by inflammatory agonists that discriminate among different endothelial cell phenotypes along the pulmonary circulation. At the present time, the physiologic significance of perivascular cuff formation and its contribution to lung mechanics are incompletely understood.
Lung compliance is decreased in patients with ARDS. We questioned whether perivascular cuffs reduce either dynamic or static compliance, because several lines of evidence suggest that alveolar fluid filling does not fully explain the decrease in compliance that accompanies ARDS. Surfactant replacement in ARDS patients does not increase tidal volume or decrease peak pressure (11) , suggesting that mechanisms other than surfactant inactivation lead to the mechanical changes in lungs of ARDS patients (11) . During experimentally induced hydrostatic edema, pulmonary compliance decreases as fluid accumulates in perivascular cuffs, before fluid accumulation in the alveoli (12) . Furthermore, studies showing increased airway resistance in animal models of pulmonary edema (13) (14) (15) and expiratory flow limitation in ARDS patients (16) creased after thapsigargin infusion, attributable to an increase in tissue resistance that was attributed to increased tissue damping and tissue elastance. Airway resistance was not changed. Neither central venous pressure nor left ventricular end diastolic pressure was altered by thapsigargin. Heart rate did not change, although thapsigargin decreased left ventricular systolic function sufficient to reduce cardiac output by 50%. Infusion of the type 4 phosphodiesterase inhibitor, rolipram, prevented thapsigargin from inducing perivascular cuffs and decreasing lung compliance. Rolipram also normalized pressure over time and corrected the deficit in cardiac output.
Conclusions: Our findings resolve for the first time that perivascular cuff formation negatively impacts mechanical coupling between the bronchovascular bundle and the lung parenchyma, decreasing lung compliance without impacting central venous pressure. (Crit Care Med 2010; 38:1458 -1466) KEY WORDS: permeability; endothelium; thapsigargin; store-operated calcium entry; acute respiratory distress syndrome suggest that air flow may be decreased in conduit airways in lungs with interstitial fluid accumulation. Thus, alveolar flooding is not sufficient to explain the mechanical changes seen in ARDS-afflicted lungs.
We have previously demonstrated that inflammatory agonists that increase permeability across extra-alveolar vascular segments decrease dynamic compliance, whereas agonists that increase permeability across capillary segments do not change dynamic compliance (10) . Because dynamic compliance is determined by airway and tissue resistances, in the current study we sought to determine whether permeability across extra-alveolar vessels, and the resultant perivascular cuffs, decreases either airway or tissue resistances in the intact animal. Our findings indicate that perivascular cuff formation decreases both dynamic and static compliance because of an increase in tissue resistance but not an increase in airway resistance.
MATERIALS AND METHODS

Surgery and Experimental Protocol
Rats were obtained from Charles River Laboratories in North Carolina. All studies were performed using CD40 rats (weight range, 250 -450 grams) in compliance with the University of South Alabama Institutional Review Board for the care of animal subjects, in accord with the National Institutes of Health guidelines for the ethical treatment of animals. Rats were sedated with intraperitoneal ketamine (5 mg/kg) and xylazine (80 mg/ kg) and were intubated via tracheal cut-down and connected to a small animal ventilator (Scireq, Montreal, Canada). One canula (PE-50) was placed in the jugular vein. A pressuresensing catheter (Millar, Houston, TX) was also placed in the jugular vein and advanced approximately 4 cm. A volume-and pressuresensing catheter (Millar) was placed via the carotid artery into the left ventricle. Central venous pressure and left ventricular pressure and volume were amplified and recorded by a Power Lab (Colorado Springs, CO) system connected to a laptop computer. Real-time cardiac volume and heart rate were determined using PVAN software (Millar). A cannula (PE-10) was also placed in the femoral artery to allow arterial blood gas sampling. Rats were ventilated with an 8-mL/kg tidal volume at a respiratory rate of 40 to 50 breaths per minute. After surgery, 15 mins were allowed to pass before the beginning of the experiment. At 15 mins, rolipram (15 M, based on blood volume of 7 mL/100 gram body weight) or vehicle control (dimethyl sulfoxide at 10 L/100 gram body weight) was injected via the central vein. Ten minutes were allowed to pass before baseline arterial blood gas analysis and assessment of respiratory mechanics were performed. Thapsigargin (0.7 M) or vehicle control (dimethyl sulfoxide at 5 L per 100 gram body weight) was then administered. Twenty minutes after thapsigargin or dimethyl sulfoxide, respiratory mechanics and blood gases were assessed for a second time. At this point in the experiment, in five rats in each group, heart and lungs were removed en bloc and lung tissue was fixed in paraformaldehyde. The experiment was continued in another five rats in each group and albuterol was administered by nebulization (1 mg/mL ϫ 2 mins). Respiratory mechanics were then measured for a third time in this group.
Evan's Blue Dye Tracer Experiments
To determine whether thapsigargin increases alveolar fluid accumulation, tracer experiments were performed using Evan's blue dye conjugated to albumin as previously described (17, 18) . Animals were anesthetized as described in Surgery and Experimental Protocol in this article, and jugular vein catheters were placed. Evan's blue dye albumin was slowly (over the course of 5 mins) introduced into the jugular vein (20 mg/kg of body weight, 5% bovine serum albumin) and allowed to recirculate for 10 additional minutes. Thapsigargin was then slowly introduced at the indicated concentrations and allowed to recirculate for a total of 15 mins, after which time two bronchoalveolar lavages (3 mL saline) were performed. Evan's blue dye-albumin in the bronchoalveolar lavage fluid was measured using a ThermoSpectronic Helios Y spectrophotometer (ThermoSpectronic, Rochester, NY) at an excitation wavelength of 620 nm.
Bacterial Culture and Inoculation
The PA103pcrV pUCPexoY bacterial strain was used for this study and was provided by Dr. Dara W. Frank (19) . Bacteria was grown, maintained, and counted as previously described (20) . Animals were anesthetized and placed on a surgical table suspended at an approximate 75% angle. An incision was made immediately above the trachea, and the trachea was exposed by blunt dissection. Bacteria (5 ϫ 10 7 ) were introduced into the trachea in 1 mL of phosphate-buffered solution. The incision site was sutured and animals were allowed to recover for 24 hrs before the jugular vein catheter was placed, as described in the Surgery and Experimental Protocol section of this article.
Assessment of Respiratory Mechanics
Pressure/volume loops were generated by stepwise inflations and deflations of (volume x) with 1-sec breath-holds at each step. The pressure/volume points used to generate loops were those at the end of each breath-hold. The entire inflation/deflation cycle lasted 13 secs. Flexivent software (Scireq, Montreal, Quebec City, Canada) was used to calculate quasistatic pulmonary compliance and the area of the pressure/volume loops by integration.
Pulmonary resistance and elastance vary with the frequency of the applied pressure oscillation. This behavior can be modeled by a complex function of frequency called the pulmonary input impedance. Respiratory impedance was measured by using the forced oscillation technique with the Flexivent system (Scireq) (21) . Airway resistance, energy dissipation of lung tissue, and elastic properties of lung tissue were obtained by fitting impedance data to the constant phase model (22) . By applying a range of frequency oscillations to the tracheal opening, during a period of interrupted tidal ventilation, we are able to assess contributions to pulmonary mechanics of resistance to movement of air through airways (R), energy dissipation of lung tissue (G), and elastic properties of lung tissue (H).
Light Microscopy
Lungs were fixed in paraformaldehyde, and lung sections were stained with hematoxylin and eosin. To measure the area of the perivascular cuffs, a grid was superimposed over each micrograph, and the number of line intersections that occurred within the area between the outer edge of the smooth muscle and the nearest edge of alveolar septum was measured. The number of intersections per tissue section was averaged in each group.
Statistics
Dynamic compliance and cuff area statistics were analyzed by one-way analysis of variance. Hemodynamic and blood gas data, perivascular loop area, quasi-static compliance, airway resistance, energy dissipation of lung tissue, and elastic properties of lung tissue were analyzed by two-way analysis of variance with repeated measures.
RESULTS
Thapsigargin Induces Perivascular Cuff Formation Around Extra-Alveolar Vessels
Thapsigargin increases permeability in large pulmonary vessels of isolated, perfused rat and mouse lungs, but it does not increase permeability across capillary segments (6, 7, 10, 23) . In the current study we examined whether perivascular cuffs decrease the dynamic compliance by increasing tissue resistance, airway resistance, or both. Lungs from untreated rats (vehicle control dimethyl sulfoxide Ͻ0.5%) did not have perivascular cuffs ( Fig. 1A) . Thapsigargin injected into the internal jugular vein of ventilated, sedated rats caused perivascular cuff formation that was prominent in extra-alveolar vessels. However, as described previously in the isolated perfused rat model (6, 7, 10, 23) , histologic sections did not reveal alveolar flooding in thapsigargin treated animals ( Fig. 1B and Fig. 2 ).
To confirm that thapsigargin did not induce alveolar edema, rats were anesthetized and jugular vein catheters were placed. Evan's blue dye albumin was infused and allowed to recirculate before delivery of vehicle or thapsigargin. After 15 mins, bronchoalveolar lavage was performed, and the presence of Evan's blue dye albumin in the bronchoalveolar lavage fluid was measured. Consistent with Figure 1 , thapsigargin induced large perivascular cuffs but did not cause alveolar flooding ( Fig. 3 ). Whereas cuffs were filled with fluid, inflammatory cells were only seen periodically and did not appear increased when compared to vehicle control animals. Thapsigargin did not increase Evan's blue dye albumin in the bronchoalveolar lavage fluid, indicating there was no increase in alveolar edema. To ensure we could measure an increase in Evan's blue dye albumin in the alveolus, we developed a Pseudomonas aeruginosa model of pneumonia that progresses to sepsis and acute lung injury. In this case, bacteria (5 ϫ 10 7 organisms) were inoculated in the airways 24 hrs before bronchoalveolar lavage. P. aeruginosa caused pneumonia with significant alveolar consolidation and profound perivascular cuffs. Significant numbers of inflammatory cells, particularly neutrophils, were observed in the alveoli and in perivascular cuffs. Bronchoalveolar lavage revealed an approximate five-fold increase in Evan's blue dye albumin in the alveoli of P. aeruginosa-treated animals. Hence, increased leak of Evan's blue dye albumin from the circulation into the airspace can be measured using this approach. Whereas thapsigargin does not increase alveolar fluid accumulation, P. aeruginosa disrupts the alveolar-capillary barrier.
To determine whether thapsigargin impacted hemodynamic parameters that could contribute to perivascular cuff formation, we monitored stroke volume, heart rate, change in pressure over time as a reflection of systolic function, left ventricular end diastolic pressure, and central venous pressures continuously in all rats (Table 1) . Thapsigargin injection decreased cardiac output. Although heart rate was not reduced, stroke volume decreased significantly because of a reduction in systolic function. This was a limiting factor regarding the dose of thapsigargin that could be used and time required for drug delivery; thapsigargin delivery required a slow infusion lasting approximately 5 mins. Intracardiac peak systolic pressure generally remained Ͼ50 mm Hg during injection and recovered to systolic pressures Ͼ80 mm Hg after injection. Thapsigargin treatment did not change either left ventricular end diastolic pressure or central venous pressure. Blood gases were not generally impacted by thapsigargin treatment, although pH decreased after the infusion (Table 2) . Thus, it is unlikely that decreased systolic function indirectly contributed to extra-alveolar perivascular cuff formation.
Previous reports have shown that the phosphodiesterase inhibitor, rolipram, attenuates thapsigargin-induced increases in large-vessel permeability (23, 24) . Interestingly, rolipram has also been shown to attenuate increased vascular permeability in rodent models attributable ischemia/ reperfusion injury (25) , cardiopulmonary bypass (26), and high peak inflation pressures (27) . When rolipram was administered to intubated, sedated rats before administering thapsigargin, perivascular cuff formation was largely prevented (Fig. 1C  and Fig. 2 ). Hemodynamic (Table 1 ) and blood gas ( Table 2 ) parameters were not changed by the rolipram/thapsigargin treatment; rolipram prevented thapsigargin from decreasing pressure over time, stroke volume, and cardiac output. Thus, as in the isolated pump-perfused lung model, thapsigargin increases endothelial cell permeability in extra-alveolar vessels that results in perivascular cuff formation, and this effect is prevented by rolipram pretreatment.
Perivascular Cuffs Decrease Lung Compliance
Perivascular cuffs may decrease dynamic compliance by one of two mechanisms. First, perivascular cuffs may compress anatomically related bronchi and decrease airway cross sectional area, thereby increasing airway resistance ( Fig.  4) . A role for this mechanism is supported by studies in which extra-alveolar airways have reduced diameters because of pancreatitis-induced inflammatory changes in rats (28) , in excised dog lungs Figure 3 . Thapsigargin induces perivascular cuffs that are largely devoid of neutrophils, without causing alveolar edema. Evan's blue dye albumin was infused through a jugular vein catheter and allowed to recirculate before delivery of vehicle control or thapsigargin. In addition, Pseudomonas aeruginosa (P. aeruginosa) was inoculated in the airways for 24 hrs, after which time jugular vein catheters were placed and Evan's blue dye albumin delivered. A, In control animals, perivascular cuffs are negligible in all vessels, including pulmonary arteries aligning the airways (top left and right panels). Thapsigargin induces significant perivascular cuffs (middle left panel), although these cuffs are largely devoid of inflammatory cells (middle right panel). Animals inoculated with P. aeruginosa 24 hrs previously possess large perivascular cuffs (lower left panel) with evidence of neutrophil accumulation (arrows) in the cuff (lower right panel). In addition, alveolar edema, alveolar hemorrhage, and consolidation were prominent histologic findings. B, Analysis of Evan's blue dye albumin in the bronchoalveolar lavage fluid demonstrates that thapsigargin does not disrupt the alveolar-capillary barrier. P. aeruginosa-treated animals display significant increases in Evan's blue dye albumin in the lavage fluid, indicating significant alveolar edema. The Y axis refers to Evan's blue detected by optical density (OD620) at 620 nm. Cardiac output was reduced in rats treated with thapsigargin because of a decrease in contractility and stroke volume. Rolipram infusion prevented these decrements in cardiac function. Heart rate, left ventricular end-diastolic pressure, and central venous pressure were unaffected by infusions. a Significantly different from control values (p Ͻ .05).
with hydrostatic edema (29) , and when peri-bronchial edema is induced in sheep (30) . Peripheral airway resistance is also increased after an elevation in left atrial pressure and extra-alveolar edema (13) (14) (15) . Second, perivascular cuffs may reduce dynamic compliance by increasing tissue resistance. Under normal circumstances, force applied at the lung periphery by the chest wall and diaphragm is transferred along alveolar septa, such that distending pressure within any portion of the lung is equal to transpulmonary pressure (Fig. 5A, B) . Perivascular cuffs may induce local heterogeneity within the lung parenchyma and decrease the efficiency with which force is transferred from the periphery to the alveolar walls, thereby interrupting the coordinated expansion of the lung as a whole. We determined the impact of perivascular cuff formation on lung compliance. Animals were ventilated using a Flexivent respirator, which enabled measurement of dynamic and static compliances. Thapsigargin reduced dynamic compliance in a dose-dependent manner (Fig. 6 ). Remarkably, rolipram pretreatment abol-ished the thapsigargin-induced decrease in lung compliance. These data suggest that perivascular cuff formation decreases dynamic compliance, whereas rolipram pretreatment prevents perivascular cuffing and the associated decrease in dynamic compliance.
Quasi-static pressure/volume loops were generated in each rat lung. Static compliance was reduced and total area of the pressure-volume loop was increased in rats treated with thapsigargin ( Fig. 7A,  C) but remained unchanged in rats pretreated with rolipram ( Fig. 7B, D) . To learn whether perivascular cuffs increase tissue resistance, control-treated, thapsigargin-treated, and rolipram/thapsigargin-treated rats were evaluated before and after treatment using the constant phase model. This model enables the simultaneous and independent assessment of tissue and airway resistances (22) . The two components of tissue resistance, tissue damping (Fig. 8A) and tissue elastance ( Fig. 8B) , were both increased in lungs treated with thapsigargin and reduced by pretreatment with rolipram. These findings indicate that perivascular cuffs are sufficient to increase lung "stiffness" by increasing tissue resistance to volume expansion.
We next sought to determine whether perivascular cuff formation decreased airway resistance. Neither the thapsigargin nor the rolipram/thapsigargin treatments altered airway resistance, and nebulized albuterol had no impact on airway resistance ( Fig. 9A ). To ensure that increased airway resistance could be measured in our intact animal preparation, carbocholine was acutely aerosolized into the airways. Carbocholine increased airway resistance approximately three-fold, and the bronchoconstriction was acutely reversed by albuterol aerosolization (Fig.  9B) . Thus, whereas perivascular cuffs are sufficient to increase tissue resistance, they do not impact on airway resistance.
DISCUSSION
During acute lung injury, the pulmonary endothelial cell barrier is disrupted, leading to extravascular fluid accumulation within the lung interstitium. Ultimately, this fluid accumulation decreases pulmonary compliance and impairs gas exchange. Traditionally, these changes have been thought to occur as the result of increased capillary permeability that leads to alveolar fluid filling and consequent surfactant inactivation (31) . How- ever, recent work illustrates that the transpulmonary endothelium is not a homogeneous cell layer, but rather one that possesses striking functional heterogeneity, particularly in regard to barrier function (32, 33) . Capillary endothelium forms a tighter barrier than does extraalveolar arterial and venous endothelium (2, 4) . Furthermore, inflammatory and mechanical stimuli display segmentrestricted actions. Stimuli such as 14,15-epoxyeicosatrienoic acid (6) and high vascular pressure (34) increase capillary permeability without increasing permeability in extra-alveolar segments. Stimuli such as thapsigargin (6, 7, 10, 23), thrombin (35) , clostridium toxin (36), and alpha-naphthylthiourea (5) increase permeability in extra-alveolar segments without increasing capillary permeability. Relatively little consideration is given to the physiologic impact of perivascular cuffs that are caused by agonists such as thapsigargin, despite evidence for cuff formation in high-altitude pulmonary edema (9) and ARDS (37, 38) . Here, we show that perivascular cuff formation is sufficient to produce decrements in pulmonary mechanics. Lung injury is accompanied by impaired pulmonary mechanics, which negatively affect both the ability to mechanically ventilate critically ill patients and to wean them from the ventilator. The original ARDS criteria included a decrease in pulmonary compliance (39) . Although decreased compliance has since been removed from the definition, investigations of causes of decreased pulmonary compliance during ARDS have continued. Findings of lower mortality in patients ventilated with lower volumes and lower peak pressures have highlighted the importance of considering effects of positive pressure ventilation on injured lungs (37) . Our work shows that extra-alveolar endothelium possesses intrinsic signaling pathways that, when activated, lead exclusively to large vessel leak and increased airway pressure at any given lung volume (decreased compliance). This decrease in compliance is attributable to the presence of perivascular cuffs that increase tissue resistance without increasing airway resistance. Previous studies have shown a role for both increased tissue resistance and increased airway resistance in patients with ARDS. Our present observations suggest that the perivascular cuffs that accompany ALI/ ARDS contribute to the decrease in compliance observed in these patients by impairing efficient mechanical coupling between the bronchovascular bundle and the lung parenchyma.
Previous studies indicate that thapsigargin directly induces inter-endothelial cell gap formation (2, 6, 7, 40) . Our present studies support this idea, because thapsigargin induced perivascular cuffs without a concurrent increase in either central venous pressure or left ventricular end diastolic volume; it is unlikely that thapsigargin treatment increased the hydrostatic pressure in the pulmonary circulation. Nonetheless, thapsigargin treatment did impact on cardiac function, because a large decrease in cardiac output was noted. Thapsigargin inhibits the ATP-dependent sarcoplasmic, endoplasmic reticulum ATPase, which maintains high calcium concentrations within the sarcoplasmic reticulum (41) . The thapsigargin-induced depletion of stored Thapsigargin increases pressure-volume loop area. A, Representative pressure-volume curve from thapsigargin-treated rats, before and after treatment, demonstrate that thapsigargin right shifts the curve, increasing the pressure required to achieve any volume. B, Representative pressure-volume curve from rolipram and thapsigargin-treated rats, before and after treatment, illustrates that rolipram infusion prevents the decrease in lung compliance, normalizing the pressure-volume curve. Average data show that thapsigargin decreases static compliance (C) and increases the pressure-volume loop area (D), which are effects that are inhibited by rolipram infusion. *Different from pre-thapsigargin value (p Ͻ .05). calcium activates calcium entry across the plasma membrane through so-called store-operated calcium entry channels (42) . The endoplasmic reticulum ATPase calcium store is an important calcium source that modulates both cardiac excitability (43) and contractility (44) . In pacemaker cells inhibition of calcium release from the sarcoplasmic reticulum reduces heart rate (45) (46) (47) , whereas increasing endoplasmic reticulum ATPase expression promotes cardiac contractility (48 -50) . We did not observe a change in heart rate after thapsigargin infusion, although cardiac output was significantly reduced. The decrease in cardiac output occurred because of a decrease in stroke volume, as direct pressure over time measurements revealed a decrease in systolic function. It is not clear how thapsigargin decreased systolic function without changing heart rate. One explanation may be found in the recent description of store operated calcium entry in cardiac myocytes (51, 52) . Depletion of the sar-coplasmic reticulum calcium store may reduce actinomycin interaction and thereby decrease cardiac contractility while simultaneously activating storeoperated calcium entry that is sufficient to maintain pacemaker function. Overall, our present findings are compatible with those reporting cardioprotective and inotropic actions of the endoplasmic reticulum ATPase (48 -50) .
Whereas the data reported suggest that perivascular cuffs impair coupling between the bronchovascular bundle and the tissue, we must consider alternate explanations that may contribute to decreased lung compliance. For example, thapsigargin may directly activate contractile machinery that increases resistance against tissue expansion, along the bronchovascular bundle and then in the microcirculation. Thapsigargin causes contraction of both pulmonary artery endothelial cells (53, 54) and smooth muscle cells (55) (56) (57) in culture experiments. In the isolated perfused lung, thapsigar-gin infusion may cause a small, transient increase in resistance (7, 58) . However, in the normotensive circulation this effect is negligible, primarily because thapsigargin also induces endothelial production of nitric oxide and prostacyclin. Inhibiting nitric oxide production reveals a large, sustained, thapsigargin-induced contraction in the isolated perfused lung. The idea that thapsigargin induces endothelial cell gap formation that is accompanied by stress fiber formation while at the same time inducing nitric oxide production is very interesting and likely illustrates how calcium signals can be used to accomplish diverse physiologic outcomes. However, at present, there is no evidence that thapsigargin can stiffen the pulmonary artery vessel wall in a way that may impact tissue expansion. Thapsigargin induces pulmonary microvascular endothelial cell contraction but, by itself, does not induce gaps in these cells (23, 40) . This observation suggests thapsigargin could stiffen the cell. Whether such phenomena occur in vivo is unclear. Furthermore, it is not evident whether decreased microvascular compliance could represent a mechanism limiting tissue expansion. Future studies would have to test this possibility. Second, we consider whether reduced cardiac contractility increases blood volume in the pulmonary circulation that impairs vascular compliance and consequently limits respiratory mechanics. In this case, rolipram treatment not only normalized perivascular cuff formation and lung mechanics but also normalized contractility. We would anticipate that if this were the cause of impaired lung mechanics, then an increase in left ventricular end diastolic pressure would accompany the decrease in contractility, or perhaps be manifest either physiologically as an increase in central venous pressure or pathologically as vascular congestion. An increase in neither central venous pressure nor vascular congestion was observed in thapsigargin-treated animals. Thus, this is an unlikely cause of limited tissue expansion, although we cannot fully exclude this explanation as a contributing factor.
CONCLUSION
In summary, by utilizing an agonist that induces perivascular cuff formation, without concomitant alveolar edema, we provide novel insight into how perivascular cuffs influence pulmonary mechanics. Our findings illustrate that perivascular cuffs that form along extra-alveolar vessels increase tissue resistance without affecting airway resistance and, in so doing, decrease lung compliance. Furthermore, we provide evidence that the type 4 phosphodiesterase inhibitor, rolipram, acutely prevents perivascular cuff formation and abnormal lung mechanics. A clinical correlate to the physiology we have described may exist in patients in whom extubation fails despite normal preextubation blood gases. Such patients may have perivascular cuffs that decrease their chance of successful extubation because of the high work of breathing. Future studies will determine whether prophylactic type 4 phosphodiesterase inhibition represents a novel approach to improve the success of weaning in patients at high risk for failed extubation.
